AlphaFold & Beyond: AI in Drug Discovery — What Researchers Are Saying

The AlphaFold Inflection Point

When DeepMind released AlphaFold 2 in 2021, it solved the protein folding problem that had stymied structural biologists for 50 years. AlphaFold 3, released in 2024, extended this to protein-DNA, protein-RNA, and crucially — protein-ligand complexes. This single capability change transformed AlphaFold from a structural biology tool into a drug discovery accelerator.

Traditional structure-based drug design required experimental protein structures — obtainable only through X-ray crystallography, cryo-EM, or NMR, each taking months and significant resources. AlphaFold 3 now provides accurate structural predictions in minutes, enabling virtual screening at a scale previously impossible.

What This Means for Hit Identification

In drug discovery, "hit identification" is the process of finding compounds that bind to a disease-relevant target. Traditionally, this involved screening 100,000–1,000,000 compounds from chemical libraries — a process taking 12–18 months and costing tens of millions of dollars. With AlphaFold 3-guided virtual screening, researchers narrow this to 100–1,000 high-probability candidates before any wet lab work begins. The time savings are dramatic.

Generative Chemistry: Designing Drugs From First Principles

Beyond screening existing compounds, generative AI models are now designing entirely new molecular structures with specific pharmacological properties. These models — trained on millions of known drug-target interactions — generate novel chemical entities that are simultaneously optimized for binding affinity, selectivity, synthetic accessibility, and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties.

Graph Neural Networks and Molecular Design

Graph Neural Networks (GNNs) have emerged as the dominant architecture for molecular property prediction. Molecules are naturally represented as graphs — atoms as nodes, bonds as edges — and GNNs can capture the complex 3D spatial relationships that determine how a molecule interacts with a biological target. When paired with reinforcement learning, GNNs can iteratively improve molecular designs toward a specified optimization target.

Several 2025-2026 studies have demonstrated GNN-generated candidates progressing to preclinical trials within 18 months of initial design — a timeline that would have been considered impossible in traditional discovery paradigms.

Drug Repurposing: The Low-Hanging Fruit

AI-driven drug repurposing — identifying new therapeutic uses for approved drugs — offers a particularly compelling value proposition: approved drugs have known safety profiles, dramatically reducing the regulatory pathway. Knowledge graph-based AI models, which encode relationships between diseases, genes, proteins, and drugs, have proven especially effective at identifying repurposing opportunities.

A 2026 paper published in Nature Communications used a multi-relational graph embedding approach to identify 7 approved drugs with computationally predicted efficacy against CRE (carbapenem-resistant Enterobacteriaceae) — a critical AMR pathogen. Three of these candidates are now in early experimental validation.

The Indian Pharmaceutical Opportunity

India's generic pharmaceutical sector — the world's third-largest by volume — is beginning to explore AI integration. While generics manufacturing doesn't require de novo drug discovery, AI is enabling Indian companies to identify niche therapeutic areas, optimize formulation chemistry, and accelerate biosimilar development. Several large pharma players, including Sun Pharma and Cipla, have announced AI partnerships specifically for this purpose.

Genomics + AI: Personalizing the Target

Drug discovery doesn't happen in isolation from genetics. The integration of large-scale genomic data — from biobanks, GWAS studies, and single-cell sequencing — with AI is enabling the identification of genetically-validated drug targets with much higher clinical success probability. Drugs targeting genetically-validated genes have approximately twice the clinical success rate of those that don't.